These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35072565)

  • 1. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials.
    Cammarota A; Zanuso V; D'Alessio A; Pressiani T; Personeni N; Rimassa L
    Expert Opin Investig Drugs; 2022 Apr; 31(4):401-413. PubMed ID: 35072565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
    El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
    Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
    Kelley RK; W Oliver J; Hazra S; Benzaghou F; Yau T; Cheng AL; Rimassa L
    Future Oncol; 2020 Jul; 16(21):1525-1536. PubMed ID: 32491932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
    Chan SL; Ryoo BY; Mo F; Chan LL; Cheon J; Li L; Wong KH; Yim N; Kim H; Yoo C
    J Hepatol; 2024 Aug; 81(2):258-264. PubMed ID: 38570034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib for the treatment of hepatocellular carcinoma.
    Personeni N; Rimassa L; Pressiani T; Smiroldo V; Santoro A
    Expert Rev Anticancer Ther; 2019 Oct; 19(10):847-855. PubMed ID: 31603008
    [No Abstract]   [Full Text] [Related]  

  • 6. Cabozantinib as a second-line treatment option in hepatocellular carcinoma.
    D'Angelo A; Sobhani N; Bagby S; Casadei-Gardini A; Roviello G
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):623-629. PubMed ID: 32394749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
    Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
    Shang R; Song X; Wang P; Zhou Y; Lu X; Wang J; Xu M; Chen X; Utpatel K; Che L; Liang B; Cigliano A; Evert M; Calvisi DF; Chen X
    Gut; 2021 Sep; 70(9):1746-1757. PubMed ID: 33144318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy.
    Ji F; Nguyen MH
    Lancet Oncol; 2022 Aug; 23(8):962-963. PubMed ID: 35798015
    [No Abstract]   [Full Text] [Related]  

  • 12. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.
    Deeks ED
    Target Oncol; 2019 Feb; 14(1):107-113. PubMed ID: 30767164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
    Zhang CH; Li M; Lin YP; Gao Q
    Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials.
    Di Federico A; Rizzo A; Carloni R; De Giglio A; Bruno R; Ricci D; Brandi G
    Expert Opin Investig Drugs; 2022 Apr; 31(4):361-369. PubMed ID: 34798793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
    Wong KM; King GG; Harris WP
    Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma.
    D'Alessio A; Cammarota A; Zanuso V; Pressiani T; Personeni N; Rimassa L
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):927-939. PubMed ID: 34167423
    [No Abstract]   [Full Text] [Related]  

  • 20. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
    Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
    Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.